Drug Trial Radar · NCT07108153
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Nov 3, 2025
Primary completion
Jun 25, 2026
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- Sionna Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
Conditions
- Cystic Fibrosis (CF)
Interventions
SION-719Drug
All participants receive SION-719, as specified by their treatment sequence assignment
Placebo-to-match SION-719Drug
All participants receive placebo to match SION-719, as specified by their treatment sequence assignment
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed TrikaftaTime frame: Day 1 through day 57
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
National Jewish Health
Denver, Colorado
University of Iowa
Iowa City, Iowa
Johns Hopkins
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
Washington University
St Louis, Missouri
New York Medical College
Hawthorne, New York
Columbia University
New York, New York
University Hospital of Cleveland
Cleveland, Ohio
Medical University of South Carolina
Charleston, South Carolina
University of Washington
Seattle, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Gold Coast University Hospital
Southport, Queensland, Australia
Monash University
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.